AMRX
Price
$9.61
Change
-$0.13 (-1.33%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
3.06B
50 days until earnings call
RDY
Price
$14.86
Change
+$0.13 (+0.88%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
12.38B
37 days until earnings call
Interact to see
Advertisement

AMRX vs RDY

Header iconAMRX vs RDY Comparison
Open Charts AMRX vs RDYBanner chart's image
Amneal Pharmaceuticals
Price$9.61
Change-$0.13 (-1.33%)
Volume$39.56K
Capitalization3.06B
Dr. Reddy's Laboratories
Price$14.86
Change+$0.13 (+0.88%)
Volume$4.57K
Capitalization12.38B
AMRX vs RDY Comparison Chart in %
Loading...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. RDY commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a StrongBuy and RDY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (AMRX: $9.61 vs. RDY: $14.86)
Brand notoriety: AMRX and RDY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 147% vs. RDY: 139%
Market capitalization -- AMRX: $3.06B vs. RDY: $12.38B
AMRX [@Pharmaceuticals: Generic] is valued at $3.06B. RDY’s [@Pharmaceuticals: Generic] market capitalization is $12.38B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.35B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileRDY’s FA Score has 0 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • RDY’s FA Score: 0 green, 5 red.
According to our system of comparison, AMRX is a better buy in the long-term than RDY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while RDY’s TA Score has 6 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 5 bearish.
  • RDY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RDY is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а -2.14% price change this week, while RDY (@Pharmaceuticals: Generic) price change was +1.92% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +26.07%. For the same industry, the average monthly price growth was +25.64%, and the average quarterly price growth was +59.72%.

Reported Earning Dates

AMRX is expected to report earnings on Nov 07, 2025.

RDY is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+26.07% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($12.4B) has a higher market cap than AMRX($3.06B). AMRX has higher P/E ratio than RDY: AMRX (961.00) vs RDY (19.23). AMRX YTD gains are higher at: 21.338 vs. RDY (-5.301). RDY has higher annual earnings (EBITDA): 98.1B vs. AMRX (584M). RDY has more cash in the bank: 66.7B vs. AMRX (71.5M). AMRX has less debt than RDY: AMRX (2.58B) vs RDY (48.6B). RDY has higher revenues than AMRX: RDY (334B) vs AMRX (2.85B).
AMRXRDYAMRX / RDY
Capitalization3.06B12.4B25%
EBITDA584M98.1B1%
Gain YTD21.338-5.301-403%
P/E Ratio961.0019.234,998%
Revenue2.85B334B1%
Total Cash71.5M66.7B0%
Total Debt2.58B48.6B5%
FUNDAMENTALS RATINGS
AMRX vs RDY: Fundamental Ratings
AMRX
RDY
OUTLOOK RATING
1..100
2067
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
4848
SMR RATING
1..100
9952
PRICE GROWTH RATING
1..100
4757
P/E GROWTH RATING
1..100
2952
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RDY's Valuation (79) in the Pharmaceuticals Generic industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that RDY’s stock grew similarly to AMRX’s over the last 12 months.

RDY's Profit vs Risk Rating (48) in the Pharmaceuticals Generic industry is in the same range as AMRX (48) in the Pharmaceuticals Major industry. This means that RDY’s stock grew similarly to AMRX’s over the last 12 months.

RDY's SMR Rating (52) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that RDY’s stock grew somewhat faster than AMRX’s over the last 12 months.

AMRX's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as RDY (57) in the Pharmaceuticals Generic industry. This means that AMRX’s stock grew similarly to RDY’s over the last 12 months.

AMRX's P/E Growth Rating (29) in the Pharmaceuticals Major industry is in the same range as RDY (52) in the Pharmaceuticals Generic industry. This means that AMRX’s stock grew similarly to RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXRDY
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
54%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
47%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 3 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 27 days ago
50%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 3 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
60%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
43%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCLVX22.89N/A
N/A
PACE Large Co Value Equity P
FSPTX41.65N/A
N/A
Fidelity Select Technology
FOVIX28.36N/A
N/A
First Trust/Confluence Small Cap Val I
OGIIX53.69N/A
N/A
Invesco Global Opportunities R6
ADNPX21.59-0.08
-0.37%
American Beacon ARK Transfmt Innov Inv

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and HROW have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and HROW's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+0.88%
HROW - RDY
30%
Poorly correlated
+0.50%
COLL - RDY
29%
Poorly correlated
-0.25%
AVDL - RDY
27%
Poorly correlated
+1.62%
VTRS - RDY
27%
Poorly correlated
+0.63%
AMRX - RDY
25%
Poorly correlated
-1.33%
More